Shakila P. Khan

TL;DR: A phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors did not detect significant survival differences, and exploratory analyses of secondary end points indicated that peripheral- Blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduceThe risk of chronic GVHD.

TL;DR: Hemophagocytic lymphohistiocytosis is a life‐threatening hyperinflammatory syndrome that remains difficult to treat and there are no large studies of second‐line therapies.

TL;DR: Low-dose TBI + CY + ATG conditioning resulted in excellent outcome of unrelated transplants in patients with aplastic anemia who had received multiple transfusions, particularly with HLA-identical transplants.

TL;DR: For patients with an HLA-matched, unrelated donor, a TBI dose of 200 cGy (in combination with CY/ATG) was sufficient to allow for engraftment without inducing prohibitive toxicity, and the highest probability of survival was observed among patients who underwent transplantation within 1 year of diagnosis, compared with patients who undergone transplantation after a longer period of disease.

TL;DR: Recipients of unrelated donor BM had better psychological well-being, less burdensome chronic GVHD symptoms, and were more likely to return to work than recipients of PB at 5 years after transplantation.